Previous 10 | Next 10 |
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papilloma...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Q1 2024 revenue of $45.0 million Q1 2024 GAAP Net Loss of $4.5 million and positive Adjusted EBITDA of $3.8 million Fifth consecutive quarter of positive Adjusted EBITDA Inseego Corp. (Nasdaq: INSG) (the “Company”), a technology leader in 5G mobile and ...
2024-05-05 08:54:00 ET Some investors might remember Inovio Pharmaceuticals (NASDAQ: INO) ; others might not. The small-cap biotech was once racing to develop an effective coronavirus vaccine. Its bet to become a leader in this field fell flat, the company largely fell into irreleva...
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat a...
INOVIO to Participate in Upcoming Investor Conferences in May PR Newswire PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people...
2024-04-24 08:37:01 ET Summary Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent respiratory papillomatosis and VGX-3100 for HPV-r...
2024-04-23 08:29:36 ET Summary Inovio Pharmaceuticals has once again diluted its stock at far below market prices, killing its recent rally. INO's latest try at bringing a treatment to market is INO-3107, for which it expects to submit a BLA in the second half of 2024. Potenti...
Elimination of restrictive borrowing facility provides for more efficient debt capacity and cash management Inseego Corp. (Nasdaq: INSG) (the “Company”), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises, an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
2024-07-16 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today announced that the company will release its financial results for the second quarter of 2024, ended June 30, 2024, after the financial ...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respi...